Corporates
2002
Novartis Institutes for BioMedical Research, Inc.Novartis Institutes for BioMedical Research (NIBR) is the pharmaceutical research arm of Novartis, focusing on discovering innovative new drugs and therapies. NIBR employs around 6,000 scientists and physicians globally and has a strong focus on collaboration, both internally and externally with academic and industry partners. Their research spans various disease areas and utilizes advanced technologies like machine learning in drug discovery.
NIBR does:
Drug Discovery: NIBR's primary goal is to identify and develop new pharmaceutical treatments for a wide range of diseases.
Collaboration: NIBR actively collaborates with external institutions and industries to accelerate research and development.
Research Areas: NIBR's research spans various disease areas, including oncology, cardiovascular diseases, and more.
Technology: NIBR utilizes advanced technologies, including machine learning, to aid in drug discovery and development.
Clinical Trials: NIBR's research also includes early-phase clinical trials to test potential therapies in humans, according to Novartis.
NIBR does:
Drug Discovery: NIBR's primary goal is to identify and develop new pharmaceutical treatments for a wide range of diseases.
Collaboration: NIBR actively collaborates with external institutions and industries to accelerate research and development.
Research Areas: NIBR's research spans various disease areas, including oncology, cardiovascular diseases, and more.
Technology: NIBR utilizes advanced technologies, including machine learning, to aid in drug discovery and development.
Clinical Trials: NIBR's research also includes early-phase clinical trials to test potential therapies in humans, according to Novartis.
Address
Cambridgeport 250, 02139 Cambridge, United States of America